Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT101 in CAP with Sepsis
NCT06669403Phase 1Not yet recruiting
- Sponsor
- Op-T
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OPT101 in sepsis and community acquired pneumonia (CAP) (3 arms), sponsored by Op-T. Primary endpoints: Treatment-Emergent Adverse Events at 30 days, Serious Adverse Events at 30 days and 2 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
OPT101
03
Conditions
sepsiscommunity acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT06669403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669403.